Why Myriad Genetics (MYGN) Stock Is Trading Up Today [Yahoo! Finance]
Myriad Genetics (NASDAQ:MYGN) had its price target lowered by analysts at Wells Fargo & Company from $6.50 to $6.00. They now have an "equal weight" rating on the stock.
Myriad Genetics (NASDAQ:MYGN) had its "neutral" rating reaffirmed by analysts at UBS Group AG.
Six presented abstracts at ASCO-GU 2026 reinforce the clinical impact of Myriad’s Precise MRD, Prolaris, and MyRisk tests
Myriad Genetics Inc (MYGN) Q4 2025 Earnings Call Highlights: Surpassing Revenue Expectations ... [Yahoo! Finance]